How should polyneuropathy be evaluated and managed?

Evaluation and Management of Polyneuropathy

Initial Clinical Assessment

Begin with a focused neurological examination targeting specific fiber types and distribution patterns to establish the diagnosis and guide further testing. 1

Symptom Characterization

• Sensory symptoms typically present as burning pain, tingling, numbness, or "electric shock" sensations starting distally in the feet and progressing proximally in a symmetric pattern 1, 2
• Nocturnal exacerbation of neuropathic pain is characteristic and should be specifically queried 2
• Autonomic manifestations including orthostatic dizziness, erectile dysfunction, gastroparesis-type symptoms, or bladder dysfunction indicate autonomic fiber involvement 1, 3

Physical Examination - Fiber-Specific Testing

The examination must systematically assess both small and large fiber function:

• Small-fiber assessment: Test pin-prick and temperature sensation in distal lower extremities to detect small-fiber loss 1, 2
• Large-fiber assessment: Use a 128-Hz tuning fork at the great toes and malleoli to evaluate vibration perception 1, 4
• Protective sensation: Perform 10-g monofilament testing on plantar surfaces to identify loss of protective sensation and predict ulceration risk 1, 4
• Motor screening: Examine for distal weakness, muscle atrophy, and ankle reflexes 1, 2

Critical pitfall: Normal nerve conduction studies do not exclude polyneuropathy, as small fibers constitute 70-90% of peripheral nerves and are affected earliest but not detected by standard electrodiagnostic testing 1

Laboratory Evaluation

Order a focused laboratory panel to identify treatable causes, prioritizing the highest-yield tests:

First-Line Screening (Highest Yield)

• Fasting plasma glucose and HbA1c - diabetes is the most common cause of polyneuropathy in Europe and North America 3, 1, 5
• Serum B12 level - deficiency found in approximately 3.6% of patients with polyneuropathy 3
• Serum protein immunofixation electrophoresis - abnormal in approximately 9% of patients 3
• Comprehensive metabolic panel (renal function, liver function, electrolytes) 3, 1
• Complete blood count and erythrocyte sedimentation rate 3
• Thyroid function tests 3

Enhanced B12 Assessment

• Methylmalonic acid and homocysteine levels should be measured when serum B12 is in the low-normal range (200-400 pg/mL), as these metabolites are elevated in 5-10% of such patients 3

Additional Testing Based on Clinical Context

• Exclude alternative causes only when presentation is atypical (asymmetric distribution, rapid progression, motor predominance, upper extremity involvement) 4, 2
• Consider cervical/lumbar imaging for nerve root compression or spinal stenosis 2
• Review medications for neurotoxic agents (chemotherapy, nitrofurantoin) 2

Important distinction: Laboratory tests do not diagnose polyneuropathy—they only exclude alternative diagnoses. The diagnosis is clinical, based on symptoms and examination findings 4

Electrodiagnostic Testing

Nerve conduction studies (NCS) and electromyography (EMG) are indicated selectively, not routinely:

• When NCS/EMG is helpful: Differentiating axonal from demyelinating patterns, confirming diagnosis when clinical findings are equivocal, or when features are atypical 2, 6
• When NCS/EMG is normal: This does not exclude small-fiber neuropathy; proceed to skin biopsy for intraepidermal nerve fiber density measurement 1, 2
• Referral to neurology: Reserve for atypical presentations only 4

Disease-Specific Management

Diabetic Polyneuropathy

Tight glycemic control is the only disease-modifying intervention with proven efficacy:

• Target HbA1c < 7% to prevent onset in type 1 diabetes and slow progression in type 2 diabetes 1
• Annual screening: Perform 10-g monofilament testing yearly starting at type 2 diabetes diagnosis or 5 years after type 1 diabetes diagnosis 4

ATTRv Polyneuropathy (Hereditary Transthyretin Amyloidosis)

TTR silencers are disease-modifying therapies that slow or reverse progression:

• First-line disease-directed therapy: Patisiran, inotersen, or vutrisiran reduce progression and may improve neuropathy measures 3
• Early treatment is critical: Patients treated earlier have better neuropathy impairment scores and quality of life than those whose treatment is delayed by ≥1 year 3
• Mandatory supplementation: Vitamin A 3,000 IU daily is required with all TTR silencers, as transthyretin normally transports retinol 3
• Patisiran-specific: Pre-medicate with corticosteroid, acetaminophen, and H1/H2 antihistamines at least 60 minutes before infusion to prevent infusion reactions 3
• Inotersen-specific: Monitor platelet counts weekly and serum creatinine plus urine protein-creatinine ratio every 2 weeks due to risks of thrombocytopenia and glomerulonephritis 3

Note: Tafamidis and diflunisal (TTR stabilizers) slow ATTRv polyneuropathy progression but tafamidis lacks FDA approval for this indication 3

Immune Checkpoint Inhibitor-Related Polyneuropathy

Graded management based on severity:

• Grade 1 (mild, no functional interference): Hold immune checkpoint inhibitor (ICPi) and monitor symptoms for one week; if continuing ICPi, monitor very closely for progression 3
• Grade 2 (moderate, some ADL interference): Hold ICPi and resume only when returned to Grade 1; initiate prednisone 0.5-1 mg/kg/day if progressing; add gabapentin, pregabalin, or duloxetine for pain 3
• Grade 3-4 (severe, limiting self-care): Permanently discontinue ICPi; admit patient; initiate IV methylprednisolone 2-4 mg/kg/day; obtain neurology consultation immediately 3

Workup for Grade 2-4: MRI spine with/without contrast, consider lumbar puncture (CSF analysis), EMG/NCS, and screen for alternative causes (diabetes, B12, HIV, paraproteinemia, amyloidosis) 3

Symptomatic Pain Management

First-line pharmacological options for neuropathic pain (choose one based on comorbidities):

Medication Selection Algorithm

Start with one of these three classes 3:

1. Tricyclic antidepressants (TCAs) - effective but avoid in patients with:

   • Glaucoma 3
   • Orthostatic hypotension 3
   • Cardiovascular disease 3
   • Risk of falls/unsteadiness 3
   • Autonomic symptoms (urinary retention, constipation) 3

2. Duloxetine (SNRI) - avoid in hepatic disease 3

3. Pregabalin or gabapentin (α2δ agonists) - avoid in patients with edema 3

Second-Line Therapy

• If pain control inadequate with first-line monotherapy: Switch to an alternative first-line agent from a different class 3
• If still inadequate: Add an opioid agonist (tramadol, morphine, or oxycodone-controlled release) as combination therapy 3

Important consideration: Older patients with amyloidosis are at greater risk for medication side effects; consult the Beers Criteria for potentially inappropriate medications in older adults 3

Autonomic Symptom Management

For orthostatic hypotension (common in amyloid and autonomic neuropathy):

• Non-pharmacological first: Increased fluid intake, salt tablets, compression stockings (knee- or thigh-high), abdominal binders 3
• Pharmacological options (use cautiously in heart failure):
  • Fludrocortisone, midodrine, or droxidopa - may cause fluid retention or supine hypertension 3
  • Pyridostigmine - preferred option without risks of fluid retention or supine hypertension 3

Caution: Fludrocortisone, midodrine, and droxidopa may be poorly tolerated in patients with cardiac involvement and restrictive physiology 3

Monitoring and Complication Prevention

Annual protective-sensation testing is mandatory:

• Perform 10-g monofilament testing yearly to detect emerging loss of protective sensation 1, 4
• Foot-care education: Counsel on daily foot inspection, proper footwear selection, and prompt reporting of skin changes to reduce ulcer risk 1
• Physical therapy and occupational therapy: Beneficial for functional deficits depending on symptoms 3

Common Pitfalls to Avoid

• Do not rely on NCS alone: Small-fiber neuropathy requires skin biopsy when NCS is normal but clinical suspicion is high 1
• Do not assume a single etiology: Multiple factors (alcohol, impaired glucose tolerance, vitamin deficiencies) frequently coexist 1
• Do not use monofilament alone to diagnose neuropathy: It identifies loss of protective sensation, not early neuropathic changes; combine with 128-Hz tuning fork testing 4
• Do not delay treatment in ATTRv: Early initiation of TTR silencers significantly improves outcomes compared to delayed treatment 3